NASDAQ:NLSP NLS Pharmaceutics - NLSP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NLS Pharmaceutics AG Please log in to your account or sign up in order to add this asset to your watchlist. $1.50 -0.01 (-0.66%) (As of 03/17/2023 08:54 PM ET) Add Compare Share Share Today's Range$1.45▼$1.5950-Day Range$1.30▼$1.8252-Week Range$0.33▼$1.88Volume51,900 shsAverage Volume85,379 shsMarket Capitalization$17.67 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NLS Pharmaceutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside233.3% Upside$5.00 Price TargetShort InterestHealthy0.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 stars 3.5 Analyst's Opinion Consensus RatingNLS Pharmaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, NLS Pharmaceutics has a forecasted upside of 233.3% from its current price of $1.50.Amount of Analyst CoverageNLS Pharmaceutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.73% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NLSP. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added NLS Pharmaceutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.98% of the stock of NLS Pharmaceutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 30.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NLS Pharmaceutics (NASDAQ:NLSP) StockNLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.Read More Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLSP Stock News HeadlinesMarch 1, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Present at the 35th Annual Roth ConferenceMarch 1, 2023 | finance.yahoo.comNLS Pharmaceutics to Present at the 35th Annual Roth ConferenceMarch 20, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 31, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on NLS Pharmaceutics (NLSP)January 30, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of NarcolepsyJanuary 25, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity RequirementJanuary 25, 2023 | finance.yahoo.comNLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity RequirementJanuary 23, 2023 | finance.yahoo.comNLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor ActivityMarch 20, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.January 12, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price RequirementJanuary 12, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical CompoundsJanuary 12, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Compliance with Nasdaq Bid Price RequirementJanuary 12, 2023 | finance.yahoo.comNLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical CompoundsJanuary 11, 2023 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in Upcoming Investor ConferencesJanuary 10, 2023 | finance.yahoo.comNLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong KongDecember 20, 2022 | finance.yahoo.comNLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037December 14, 2022 | finance.yahoo.comNLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.December 7, 2022 | finance.yahoo.comNLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 MillionDecember 1, 2022 | finance.yahoo.comNLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use DisorderNovember 23, 2022 | finance.yahoo.comNLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in EuropeNovember 14, 2022 | finance.yahoo.comNLS Pharmaceutics Successfully Appeals Nasdaq Delisting NoticeNovember 7, 2022 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience in the Treatment of NarcolepsyNovember 7, 2022 | finance.yahoo.comNLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of NarcolepsyNovember 2, 2022 | finanznachrichten.deNLS Pharmaceutics AG: U.S. FDA Grants Orphan Drug Designation for Quilience for the Treatment of Idiopathic HypersomniaNovember 2, 2022 | finance.yahoo.comU.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)October 5, 2022 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term NotesOctober 5, 2022 | finance.yahoo.comNLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NLSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLSP Company Calendar Today3/20/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NLSP CUSIPN/A CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book30.00Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.83 Key ExecutivesMr. Alexander Zwyer M.B.A. (Age 54)Pres, CEO & Director Mr. Chad C. Hellmann M.B.A.Chief Financial OfficerMr. Eric Konofal M.D. (Age 56)Ph.D., Chief Scientific Officer Dr. Christian C. Wenger Dr. iur. (Age 59)L.L.M., LL.M., Ph.D., Gen. Counsel Ms. Sharon KeysHead of Regulatory AffairsDr. George Apostol M.D. (Age 50)Chief Medical Officer and Global Head of R&D More ExecutivesKey CompetitorsPharvarisNASDAQ:PHVSQilian International Holding GroupNASDAQ:QLI111NASDAQ:YIAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWView All Competitors NLSP Stock - Frequently Asked Questions Should I buy or sell NLS Pharmaceutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NLSP shares. View NLSP analyst ratings or view top-rated stocks. What is NLS Pharmaceutics' stock price forecast for 2023? 3 brokers have issued 12 month price targets for NLS Pharmaceutics' shares. Their NLSP share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View analysts price targets for NLSP or view top-rated stocks among Wall Street analysts. How have NLSP shares performed in 2023? NLS Pharmaceutics' stock was trading at $1.29 at the start of the year. Since then, NLSP shares have increased by 16.3% and is now trading at $1.50. View the best growth stocks for 2023 here. When is NLS Pharmaceutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our NLSP earnings forecast. When did NLS Pharmaceutics IPO? (NLSP) raised $20 million in an initial public offering (IPO) on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager. What is NLS Pharmaceutics' stock symbol? NLS Pharmaceutics trades on the NASDAQ under the ticker symbol "NLSP." How do I buy shares of NLS Pharmaceutics? Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NLS Pharmaceutics' stock price today? One share of NLSP stock can currently be purchased for approximately $1.50. How can I contact NLS Pharmaceutics? NLS Pharmaceutics' mailing address is ALTER POSTPLATZ 2, STANS V8, CH-6370. The official website for the company is www.nlspharma.com. The company can be reached via phone at 41-44-512-2150 or via fax at 41-41-618-8009. This page (NASDAQ:NLSP) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.